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Background: Adenosine is produced at high levels at inflamed sites as a by-product of cellular activation and
breakdown. Adenosine mediates its anti-inflammatory activity primarily through the adenosine A2a receptor
(A2aR), a member of the G-protein coupled receptors. A2aR agonists have demonstrated anti-inflammatory efficacy,
however, their therapeutic utility is hindered by a lack of adenosine receptor subtype selectivity upon systemic
exposure. We sought to harness the anti-inflammatory effects of adenosine by enhancing the responsiveness of
A2aR to endogenously produced adenosine through allosteric modulation. We have identified a family of positive
allosteric modulators (PAMs) of the A2aR. Using one member of this PAM family, AEA061, we demonstrate that
A2aRs are amenable to allosteric enhancement and such enhancement produces increased A2aR signaling and
diminished inflammation in vivo.
Methods: A2aR activity was evaluated using a cell-based cAMP assay. Binding affinity of A2aR was determined
using [3H]CGS 21680. A2aR-mediated G-protein activation was quantified using [
35S]GTP-γS. The effect of AEA061
on cytokine production was evaluated using primary monocytes and splenocytes. The anti-inflammatory effect of
AEA061 was evaluated in the LPS-induced mouse model of inflammation.
Results: AEA061 had no detectable intrinsic agonist activity towards either rat or human A2aRs. AEA061 enhanced the
efficacy of adenosine to rat and human A2aRs by 11.5 and 2.8 fold respectively. AEA061 also enhanced the maximal
response by 4.2 and 2.1 fold for the rat and the human A2aR respectively. AEA061 potentiated agonist-mediated Gα
activation by 3.7 fold. Additionally, AEA061 enhanced both the affinity as well as the Bmax at the human A2aR by 1.8
and 3 fold respectively. Consistent with the anti-inflammatory role of the A2aR, allosteric enhancement with AEA061
inhibited the production of TNF-α, MIP-1α, MIP-1β, MIP-2, IL-1α, KC and RANTES by LPS-stimulated macrophages
and/or splenocytes. Moreover, AEA061 reduced circulating plasma TNF-α and MCP-1 levels and increased plasma IL-10
in endotoxemic A2aR intact, but not in A2aR deficient, mice.
Conclusions: AEA061 increases affinity and Bmax of A2aR to adenosine, thereby increasing adenosine potency and
efficacy, which translates to enhanced A2aR responsiveness. Since the A2aR negatively regulates inflammation, PAMs of
the receptor offer a novel means of modulating inflammatory processes.
Keywords: Adenosine A2a receptor, G protein-couple receptor, Allosteric enhancement, Inflammation, Positive allosteric
modulator, Inhibition of TNF-α productionBackground
Inflamed/injured tissues produce pro-inflammatory cyto-
kines such as tumor necrosis factor-alpha (TNF-α) to medi-
ate cellular processes required to remove injurious stimuli
and initiate the healing process that is essential for survival
of the organism. Cells utilize a variety of receptors and* Correspondence: awelihinda@mmrx.org
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production. For example, engagement of the pathogen-
associated pattern recognition family of receptors (TLR;
[1]) as well as antigen-dependent ligation of Fcγ receptors
(FcγR; [2]) promotes the production of pro-inflammatory
cytokines. However, if unchecked, chronic inflammation
can lead to a host of debilitating diseases such as rheuma-
toid arthritis, inflammatory bowel disease, asthma and
chronic obstructive pulmonary disease, as well as acuteed Central Ltd. This is an Open Access article distributed under the terms of the
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natural physiological mechanisms to terminate inflamma-
tion and limit tissue destruction.
Adenosine is an endogenous purine nucleoside that
regulates numerous cellular functions including inflam-
mation. Many different cell types produce and release
adenosine during normal metabolic function. In patho-
logical conditions such as inflammation, ischemia and
hypoxia, adenosine production and release are elevated
[3-5]. Endogenous adenosine is rapidly degraded and
therefore its presence is limited to sites of inflammation.
The biological activity of adenosine is mediated through
specific membrane bound G protein-coupled receptors
(GPCRs) termed P1-purinoceptors, also known as adeno-
sine receptors (AR). To date four AR subtypes have been
described [6]. Among them, A2aR is the most effective in
down-regulating inflammation through modulation of
intracellular cAMP levels [7,8]. A2aR is coupled to the
stimulatory G protein Gαs [9]. Thus, adenosine A2aR
occupation leads to an increase in intracellular cAMP
levels. The anti-inflammatory role of A2aR has been
confirmed by the observation that A2aR-deficient mice are
hypersensitive to inflammatory stimuli [10].
GPCRs initiate signaling upon agonist binding to a site
that has evolved to specifically recognize the agonist for
the respective receptors, termed orthosteric binding sites.
In addition, GPCRs also contain allosteric binding sites
that are recognized by ligands and/or synthetic small
molecules. These allosteric sites are topographically distinct
from the orthosteric sites (for review see [11,12]). There-
fore, structural features that determine ligand-binding to
the allosteric sites are different from those of the orthosteric
sites. Unlike the orthosteric ligands, allosteric ligands have
little or no intrinsic ability to activate GPCRs upon engage-
ment at the allosteric site. They modulate orthosteric
ligand-mediated receptor function through conformational
changes that result in altered affinity of orthosteric ligands
for the receptors. Therefore, allosteric ligands can modulate
and preserve the endogenous orthosteric ligand-mediated
physiological responses, a property that has been suc-
cessfully exploited for therapeutic benefit [13,14].
Activation of the A2aR using high affinity orthosteric
ligands/agonists has demonstrated efficacy in a variety of
animal models of inflammation. However, lack of in vivo
AR subtype selectivity hindered their further development.
We sought to enhance the responsiveness of A2aR to
endogenously produced adenosine by using an allosteric
ligand that positively modulates the receptor activity. Here
we report the first evidence that endogenous adenosine-
mediated A2aR activation can be enhanced using a positive
allosteric modulator, AEA061 [15]. We show that positive
allosteric modulation of the A2aR alters the Kd and Bmax of
the receptor with respect to the endogenous agonist,




Male BALB/cJ mice and A2aR null mice (C;129S-Ador-
a2atm1Jfc/J; Jackson Laboratories) were housed at 68 – 72°
F with a 12 h light/dark cycle, fed normal rodent chow and
water ad libitum and were kept in a pathogen-free environ-
ment. A protocol approved by the Animal Care and Use
Committee of the Molecular Medicine Research Institute
was used in this study.
Materials
NECA, CGS 21680, ZM 241385 and MRS 1754 were
purchased from Tocris Biosciences. [3H]CGS 21680,
GTPγ35S and WGA FlashPlates were purchased from
PerkinElmer Corporation. LPS (E. coli O111:B4), growth
media and all the reagents (unless otherwise stated) were
purchased from Sigma-Aldrich.
Cell culture
PC-12 cells (ATCC) were grown in DMEM supplemented
with 5% FBS, 10% horse serum and amphotericin B
(0.25 mg/ml). CHO-hA2aR cells were grown in DMEM/F-
12 (1:1) supplemented with 10% FBS, 2 mM glutamine and
G418 (0.2 mg/ml). All cells were maintained at 37°C in a
5% CO2 incubator.
cAMP assay
PC-12 cells were washed with and resuspended in Hanks’
balanced salt solution (HBSS), transferred to 96-well
plates (1.4×106 cells per well) and incubated with rolipram
(50 μM), adenosine, CGS 21680 and AEA061 at indicated
concentration(s) for 15–30 min at 37°C. CHO cells
expressing human A2aR (CHO-hA2aR; [16]) were seeded
in the absence of G418 in 96-well plates (2×104 cells/well)
20 h prior to assay. Assay conditions were essentially
the same as above with the exception of inclusion of
adenosine deaminase (ADA; 3U/ml) and adenosine 5′
[α,β-methylene] diphosphate (50 μM). Intracellular
cAMP levels were quantified using Parameter ELISA
kits (R&D Systems).
Radioligand binding assay
The binding affinity of adenosine to hA2aR was evalu-
ated using the [3H]-labeled A2aR-selective agonist CGS
21680. CHO-hA2aR cell membranes were prepared as
described by Gao et al., [17]. Membranes (10 mg/well)
in binding buffer (50 mM Tris pH 7.4, 10 mM MgCl2,
1 mM EDTA, 1.5 U/ml ADA) were incubated with
AEA061 (10 μM) or vehicle (DMSO) in a 96-well WGA
FlashPlate at 25°C for 15 min. After addition of [3H]CGS
21680 (0.0-110 nM), plates were incubated for an
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containing AEA061 (10 μM) and [3H]CGS 21680. Bind-
ing was quantified using a TopCount scintillation coun-
ter. Specific binding was calculated by subtracting
counts obtained in the presence of NECA (50 μM) from
total counts.
GTP binding assay
CHO-A2aR membranes were incubated in assay buffer
(75 mM Tris (pH 7.5), 12.5 mM MgCl2, 1 mM EDTA,
100 mM NaCl, 3 μM GDP and 0.5 % BSA) containing
CGS 21680 (0.0 – 1000 nM), ADA (2U/ml) and
GTPγ35S (0.4 nM) with or without AEA061 (10 μM) in
a 96-well WGA FlashPlate for 3 h at 25°C. Non-specific
binding was estimated using GTP-γ-S (10 μM). Plates
were washed twice with cold PBS and radioactivity was
quantified using a TopCount scintillation counter.
Cytokine assays
Human monocytes were isolated from buffy coat prepa-
rations (Stanford University blood bank) by depleting
other cell types using MACS monocyte isolation kit II
(Miltenyi Biotech) as suggested by the manufacturer. To
isolate mouse splenocytes, spleens were aseptically re-
moved, punctured and rinsed with RPMI 1640 medium
to yield a cell suspension. Following red blood cell lysis
with ACK buffer (Invitrogen Corporation), cells were
seeded in 96-well plates in the same medium. Splenic
monocytes/macrophages were isolated by plastic adher-
ence after incubation for 2 h at 37°C and 5% CO2,
followed by washing twice with PBS to remove nonad-
herent cells. Monocytes/macrophages were seeded in
96-well plates (2x105 cells per well) and stimulated with
phorbol 12-myristate 13-acetate (PMA; 5 ng/ml) or lipo-
polysaccharide (LPS; 5 – 50 ng/ml) in RPMI 1640 con-
taining 1% FBS for 12 h in the presence of indicated
concentration(s) of either AEA061 or NECA. For experi-
ments evaluating the effects of A2aR antagonists, cells
were pretreated for 15 min with the antagonist ZM
241385 at 37°C before stimulation with PMA. Spleno-
cytes were seeded in 96-well plates (2×105 cells per well)
and stimulated with LPS (50 ng/ml) in DMEM contain-
ing 1% FBS for 18 h in the presence of indicated concen-
trations of AEA061. Cytokine/chemokine levels in the
culture supernatants were quantified using Quantikine
ELISA kits (R&D Systems) and/or bead-based multiplex
immunoassays (Eve Technologies).
Mouse model of endotoxemia
Male 8–10 weeks old A2aR null mice (C;129-
Adora2atm1Jfc/J; Jackson laboratories) and receptor
competent BALB/cJ control mice (Jackson laboratories; n =
10-14 per group) were dosed intravenously with AEA061
(0.1, 1 and 10 mg/kg) 10 min prior to i.p. injection of LPS(20 mg/kg). Two h after LPS dosing, mice were terminally
bled under anesthesia using cardiac puncture technique.
Plasma was isolated using lithium heparin tubes and stored
at -80°C. Plasma cytokine/chemokine levels were quantified
using Quantikine ELISA kits (R&D Systems) and/or bead-
based multiplex immunoassays (Eve Technologies).
Data analysis
Data were analyzed using GraphPad Prism Software. Dose
response curves were generated by non-linear regression
with a variable slope. Synergism between adenosine and
AEA061 was analyzed using one-way ANOVA with the
Bonferroni correction.
Results
Augmentation of adenosine-mediated cAMP production
by PC-12 cells
PC-12 cells, derived from a pheochromocytoma of rat
adrenal medulla, are known to exhibit high Gαs-coupled
AR activity. Agonist-mediated activation of the ARs in
these cells leads to a significant rise in intracellular
cAMP levels. We took advantage of this quantifiable cel-
lular response to screen derivatives of a small molecule
of plant origin for the ability to potentiate adenosine-
mediated activation of endogenous ARs in intact PC-12
cells. To rule out the possibility that the elevated levels
of cAMP were due to inhibition of phosphodiesterase 4
(PDE4) by the compounds, we utilized a saturating dose
of a prototypical PDE4 inhibitor, rolipram. Using this
screening paradigm, we have identified a family of non-
agonist small molecules that modulate AR activity.
One member of this family, AEA061 [15], enhanced
adenosine-mediated cAMP production by PC-12 cells in
a dose-dependent manner (Figure 1A). The synergism
between AEA061 and adenosine was significant at 1 μM
of the compound with adenosine levels ≥1 μM (p <0.05).
Higher concentrations of AEA061 produced significant
synergism at all concentrations of adenosine (p <0.05).
On the basis of the EC50 values, AEA061 (10 μM) poten-
tiated adenosine-mediated cAMP production by 11.5
fold. This AEA061-mediated shift in agonist EC50 was
saturable, as 100 μM of AEA061 did not yield a greater
effect. In addition, AEA061 increased the maximal
response by 1.9, 2.4 and 4.2 fold at 1, 10 and 100 μM
respectively. These results demonstrate that the affinity as
well as the efficacy of adenosine at the endogenous
Gαs-coupled adenosine receptors is enhanced by AEA061.
Augmented cAMP production by PC-12 cells is mediated
through the rat A2aR (rA2aR)
There are two Gαs-coupled adenosine receptor subtypes
(A2aR and A2bR) whose activation leads to an increase in
intracellular cAMP levels [18]. Although there are
reports of A2bR expression by PC-12 cells, A2aR appears
AB
C
Figure 1 (See legend on next page.)
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Figure 1 Potentiation of agonist-mediated A2R activation in PC-12 cells. (A) AEA061 enhances adenosine-mediated cAMP production. PC-12
cells were incubated for 30 min with adenosine and AEA061. EC50 values in μM (with 95% confidence intervals in parentheses) were as follows:
control = 9.7 (7.8 – 12.0); AEA061 (1 μM) = 9.5 (7.5 – 12.2); AEA061 (10 μM) = 0.84 (0.3 – 2.4); AEA061 (100 μM) = 0.83 (0.74 – 0.94). (B) AEA061-mediated
potentiation of cAMP production is sensitive to ZM241385. PC-12 cells were pre-incubated with ZM241385 (ZM) and MRS 1754 (MRS) for 15 min prior to
treatment with adenosine (Ado; 1 μM) and AEA061 (1 μM) for additional 30 min. (C) AEA061 enhances cAMP production mediated by CGS 21680. PC-12
cells were incubated for 15 min with AEA061 and CGS 21680. Mean cAMP levels ± SD of a representative experiment in triplicates are shown.
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evaluate the role of A2aR and/or A2bR in AEA061-
mediated enhancement of cAMP production, PC-12
cells were treated with the A2aR antagonist ZM 241385
and the A2bR antagonist MRS 1754. As shown in
Figure 1B, adenosine increased cAMP production by 4.3
fold over the control and AEA061 (10 μM) enhanced
cAMP levels by an additional 11.7 fold. As expected,
ZM 241385 (1 nM and 10 nM) blocked adenosine-
mediated cAMP production. In addition, ZM 241385 at
10 nM, but not 1 nM, blunted the adenosine plus AEA061-
mediated cAMP production. In contrast, MRS 1754, an
A2bR-specific antagonist, failed to inhibit adenosine- or
adenosine plus AEA061-induced cAMP production. These
results support the notion that enhanced-cAMP production
by PC-12 cells in the presence of AEA061 is due to potenti-
ation of rA2aR but not rA2bR activity.
To further investigate the observation that AEA061-
dependent potentiation of cAMP production by PC-12
cells is due to enhanced-activation of the endogenous
rA2aR, we evaluated the effects of AEA061 on cAMP pro-
duction stimulated by the A2aR-selective adenosine analog
CGS 21680. As shown in Figure 1C, CGS 21680 increased
cAMP production in a dose-dependent fashion while the
addition of AEA061 significantly enhanced it. Synergism
between CGS 21680 and AEA061 was evident at 1 nM of
CGS 21680 and above (p <0.05 – p <0.001), confirming
our observation that the AEA061-dependent increase in
intracellular cAMP levels is mediated through the
endogenous rA2aR. Of note, AEA061, even at 100 μM, did
not induce cAMP production in the absence of the agonist,
indicating that the compound has no intrinsic activity and
that AEA061-mediated enhancement of rA2aR activity is
due to allosterism rather than agonism at the receptor.
Enhancement of affinity and efficacy of adenosine at the
human A2a receptor (hA2aR)
Since the human A2aR (hA2aR) is the most pharmacologic-
ally characterized A2aR [19] relative to other species, we in-
vestigated the hA2aR for potential allosteric modulation. As
A2aR is evolutionarily conserved in terms of sequence,
structure and function, new knowledge gained here will
serve as a guide to the A2aRs of other species. To establish
whether the hA2aR is amenable to functional enhancement,
we evaluated the effects of AEA061 on cAMP production
by CHO-hA2aR cells. As shown in Figure 2A, AEA061dose-dependently increased cAMP production by these
cells in the presence but not in the absence of adenosine.
These results demonstrate that AEA061 has no intrinsic
activity towards the hA2aR, but can allosterically augment
agonist-mediated hA2aR activity. On the basis of EC50
values, AEA061 enhanced the adenosine-mediated response
by 2.8 fold (Figure 2B). Moreover, AEA061 also increased
the maximal response by 2.1 fold. These results establish
that, similar to the rA2aR, positive allosteric modulation of
the hA2aR causes enhanced adenosine potency and efficacy
at the receptor.
Potentiation of hA2aR-coupled Gα activation
The A2aR couples to two different classes of Gα subunits.
A2aR coupling to the Gαs and Gαolf subunits that belong
to the Gs class stimulates adenylate cyclase to increase
intracellular cAMP upon agonist engagement at the recep-
tor. In contrast, Gα15 and Gα16 subunits that belong to
the Gq class couple the A2aR receptor to phospholipase C
to stimulate the production of inositol phosphates upon
receptor activation. A2aR-mediated activation of Gα sub-
units can be measured by incorporation of a radiolabeled
non-hydrolysable GTP analog, GTPγ35S, into membrane
preparations bearing the hA2aR. To investigate whether
AEA061 enhances hA2aR-coupled Gα activation, agonist-
induced increases in GTPγ35S incorporation were quanti-
fied in the presence or absence of the compound. As shown
in Figure 3A, AEA061 dose-dependently enhanced CGS
21680-induced GTPγ35S incorporation. Analysis of the
agonist dose response indicated that AEA061 potentiated
agonist-mediated Gα activation by 3.7 fold. These results
demonstrate that the responsiveness of agonist-mediated
hA2aR-coupled Gα activation is enhanced by AEA061 and
thus links AEA061 directly to A2aR activation.
Enhancement of agonist binding to hA2aR
In general, as a functional consequence of binding,
allosteric modulators alter dissociation kinetics of the
agonist. To investigate whether enhanced A2aR activa-
tion by AEA061 in the presence of agonist was due to
altered agonist binding at the receptor, equilibrium
binding studies were performed using the radiolabeled
A2aR-selective agonist CGS 21680 and membrane prepara-
tions containing hA2aR. An enhancement in receptor affin-
ity (1.8 fold) and Bmax (3 fold) was observed with AEA061






















Figure 2 Augmentation of adenosine-mediated activation of the human A2aR (hA2aR). (A) AEA061 enhances adenosine-mediated cAMP
production by the hA2aR. CHO-hA2aR cells were incubated with adenosine, and AEA061 for 15 min. Mean cAMP levels ± SEM of a representative
experiment is shown (n = 3). (B) AEA061 potentiates both the affinity and the efficacy of adenosine at the hA2aR. CHO-A2aR cells were incubated
with AEA061 and varying concentrations of adenosine for 15 min. Mean EC50 values of three experiments with SEM were 4.4 ± 1.3 nM and
1.5 ± 0.49 nM without and with AEA061 respectively. Increase in Emax by AEA061 = 2.1 ± 0.27 fold.
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agonist binding sites at the hA2aR.
Allosteric enhancement of the A2aR attenuates
pro-inflammatory cytokine and chemokine production
Activation of A2aR has been shown to inhibit TNF-α pro-
duction by monocytes/macrophages [20-22]. We therefore
investigated the effect of allosteric enhancement of A2aR
activity on TNF-α production mediated by two different
stimuli acting through two distinct signaling pathways:
stimulation of the TLR4 receptor by LPS, and protein
kinase C (PKC)/mitogen-activated protein kinase (MAPK)
activation by PMA. Consistent with the role of allosteric
enhancement of the hA2aR, AEA061 inhibited TLR4-
mediated TNF-α production by freshly-isolated human
and mouse monocytes in a dose-dependent manner with
IC50 values of 1.42 μM (Figure 5A) and 1.6 ± 0.44 μM
(Figure 5B) respectively. AEA061 also dose-dependently
inhibited TNF-α production mediated by PKC/MAPK acti-
vation in freshly isolated human monocytes (IC50 = 1.85 ±
0.9 μM, Figure 5C). In addition, we evaluated the effects of
A2aR positive allosteric modulation on the production of
cytokines and chemokines by LPS-stimulated splenocytes.
Of interest, the production and/or release of KC, IL-1α,MIP-1α, MIP-1β, MIP-2, RANTES and TNF-α were con-
sistently inhibited by allosteric enhancement of the A2aR in
a dose-dependent manner (Figure 6) while additional cyto-
kines and chemokines remained unchanged (data not
shown). A standard battery of preclinical safety pharmacol-
ogy tests on AEA061 did not reveal any toxicity or side
effects, hence ruling out cytotoxicity as a possible cause for
the inhibition of cytokine/chemokine production. Taken to-
gether, these results suggest that positive allosteric modula-
tion of the A2aR of monocytes and splenocytes is sufficient
to enhance receptor responsiveness to endogenous adeno-
sine and inhibit production of multiple pro-inflammatory
cytokines and chemokines.
A2aR antagonism dampens the allosteric enhancement-
mediated inhibition of TNF-α production by monocytes
To examine whether the inhibition of TNF-α production
by AEA061 is mediated through selective allosteric
enhancement of the A2aR, we evaluated the effects of
AEA061 in the presence and absence of the A2aR-spe-
cific antagonist, ZM 241385, on TNF-α production by
human monocytes. As a control, we used the non-
selective high affinity AR agonist, NECA, in parallel








+ CGS 21680 (30 nM)











Log CGS 21680 (nM)
A
B
Figure 3 Potentiation of hA2aR-coupled Gα activation. (A) AEA061 dose-dependently increases agonist-mediated GTPγ35S binding to membranes.
CHO-hA2aR membranes were incubated with ADA, CGS 21680 and varying concentrations of AEA061. Each data point is the mean ± SEM of replicates of 5
determinations of a representative experiment. (B) AEA061 potentiates A2aR-mediated Gα activation. CHO-hA2aR membranes were incubated with ADA,
AEA061 and varying concentrations of CGS 21680. Each data point is the mean ± SEM of replicates of 6 determinations of a representative experiment.
EC50 values with 95% confidence intervals in parenthesis were as follows: control = 3.7 nM (2.195 - 6.294); AEA061 (10 μM) = 0.99 nM (0.7810 to 1.260).
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phages and the A2aR-selective antagonist, ZM 241385,
reversed the NECA-mediated inhibition in a dose-
dependent manner (Figure 7A). Similarly, ZM 241385
blunted the inhibition of PMA-stimulated TNF-αFigure 4 Enhancement of agonist binding to hA2aR. Equilibrium bindin
vehicle control is shown. CHO-hA2aR membranes were incubated with ADA
absence of AEA061. Bmax values: control = 152 fmol/mg; AEA061 (10 μM) =
experiment performed in triplicate.production enhanced by AEA061 in a dose-dependent
manner (Figure 7B). The A2aR antagonist, ZM 241385,
at 1 μM restored PMA-stimulated TNF-α responsive-
ness in both NECA- and AEA061-treated cells. These
results support the notion that selective allostericg of [3H]CGS 21680 to hA2aR in the presence of AEA061 (10 μM) and
and varying concentrations of [3H]CGS 21680 in the presence and
470 fmol/mg. Values are mean ± SD of results of one representative
Figure 5 Dose-dependent inhibition of LPS- and PMA-stimulated TNF-α production upon allosteric potentiation of the A2AR. Human
monocytes were stimulated with LPS (5 ng/ml; A) or phorbol 12-myristate 13-acetate (PMA; 5 ng/ml; C) for 12 h whereas mouse monocytes were
stimulated with LPS (50 ng/ml; B) for 18 h in the presence of varying concentrations of AEA061. TNF-α in the culture medium was quantified as
described in Materials and Methods. Values and error bars represent means and SEMs of one of three representative experiments performed in triplicate.









































































































































































































































































































































































































































Figure 6 (See legend on next page.)
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Figure 6 Inhibition of cytokine and chemokine production by splenocytes upon allosteric enhancement of the A2AR. Mouse splenocytes
were stimulated with LPS (50 ng/ml) for 18 h in the presence of the indicated concentrations of AEA061. Cytokines/chemokines in the culture




































































































Figure 7 Reversal of AEA061-mediated inhibition of TNF-α
production by ZM 241385. Human monocytes were pretreated for
15 min with the A2AR antagonist ZM 241385 before PMA stimulation
(5 ng/ml) and incubation with either the AR agonist NECA (1 μM; A)
or AEA061 (1 μM; B) for 12 h. TNF-α in the culture medium was
quantified by ELISA. # = p <0.001 PMA versus PMA plus AEA061 or
NECA; * = p <0.05, ** = p <0.01 *** = p <0.001 PMA plus AEA061 or
NECA with ZM versus without ZM.
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more responsive to endogenous adenosine thereby further
enhancing adenosine’s anti-inflammatory activity.
Allosteric enhancement of the A2aR alters circulating plasma
levels of pro-inflammatory and anti-inflammatory cytokines
in endotoxemic A2aR+/+ mice but not in A2aR −/−mice
To further investigate the notion that allosteric en-
hancement significantly augments endogenous adenosine-
mediated A2aR activation and subsequent inhibition of
inflammation in vivo, we utilized a mouse model of endo-
toxemia. A2aR null mice and receptor competent BALB/cJ
control mice were injected intraperitoneally with LPS, and
after 2 h plasma was collected for the measurement of
cytokine and chemokine levels. In LPS-stimulated recep-
tor competent BALB/cJ mice, allosteric enhancement of
the A2aR with AEA061 at 1 and 10 mg/kg significantly
reduced plasma TNF-α and MCP-1 levels compared to
vehicle treatment (Figure 8A and B). Although AEA061 ad-
ministration reduced plasma levels of IL-12, p40, MIP1-α,
MIP-2, MIG and M-CSF relative to that of the untreated
animals, the level of reduction did not reach statistical
significance (data not shown). In contrast, AEA061 signifi-
cantly enhanced the plasma levels of the anti-inflammatory
cytokine, IL-10, at 0.1 and 10 mg/kg (Figure 8C). These
results demonstrate that positive allosteric modulation of
the A2aR enhances receptor responsiveness to endogen-
ous adenosine and down-regulates the inflammatory
cytokine cascade in vivo. The group of A2aR null mice that
received vehicle alone had higher circulating plasma TNF-α
(Figure 8D) and lower MCP-1 (Figure 8E) and IL-10
(Figure 8F) levels relative to their BALB/cJ receptor-
competent counterparts. AEA061 at any concentration did
not alter plasma levels of TNF-α, MCP-1 or IL-10 in
LPS-treated A2aR null mice. These results confirm that
selective allosteric enhancement of the A2aR by AEA061 is
responsible for the anti-inflammatory effects observed
in vivo. It is unclear why AEA061 enhanced IL-10 produc-
tion at 0.1 and 10 kg/ml in receptor competent BALB/cJ
mice yet failed to enhance IL-10 production at 1 mg/kg
while the same dose of 1 mg/kg significantly affected
TNF-α and MCP-1 production. More in depth studies are
needed to clarify this observation.
Discussion
We demonstrate that AEA061-mediated augmentation of
A2aR activity bears the hallmarks of positive allosteric
modulation. First, both the rA2aR and the hA2aR wereunresponsive to AEA061 in the absence of the agonist.
Second, affinity and maximal response of the rA2aR and
the hA2aR were enhanced by AEA061. Third, hA2aR-
coupled Gα activation was augmented by AEA061. Lastly,
affinity as well as the number of agonist binding sites at
the hA2aR were enhanced by AEA061.
The observation that positive allosteric modulator
(PAM), AEA061, increases the number of binding sites can
be explained by equilibrium receptor binding kinetics.
Agonist binding stabilizes the signaling competent active
Figure 8 Effects of allosteric enhancement on circulating plasma cytokines and chemokines in the LPS-induced mouse model of
endotoxemia. Study groups consisted of male age matched control BALB/cJ mice (open bars; A-C) and A2AR-deficient mice (closed bars; D-F).
Animals were administered either vehicle or AEA061 (0.1, 1 and 10 mg/kg) iv 10 min prior to ip injection of LPS (20 mg/kg). Plasma cytokine/
chemokine levels were quantified 2 h after LPS dosing as described in Materials and Methods. Mean plasma cytokine/chemokine levels ± SEMs of
10–14 animals per treatment group are indicated. Statistical difference between the vehicle and the treatment groups were determined by
one-way ANOVA; *, p <0.05 and **, p <0.01.
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from the inactive conformation. AEA061, stabilizes the
agonist-bound conformation of the A2aR and strengthens
this equilibrium shift further. As this assay utilizes mem-
branes, the increase in AEA061-mediated agonist binding
cannot be explained by an increase in receptor number.
Enhancement of agonist binding at the A2aR has been
reported by two groups [23,24]. Bruns and Lu reported
an increase in agonist binding to rat striatal mem-
branes when treated with the synthetic small molecule
PD10918 [23]. However, the functional consequence ofthis enhanced agonist binding was not investigated. In
a more recent study using a substituted 8-azaadenine
derivative, Georgi et al. [24] reported augmented agon-
ist binding at the human receptor as well as increased
agonist-mediated relaxation of rat aortic rings ― ob-
servations which were attributed to allosteric modula-
tion. Further studies are necessary, however, to fully
support the postulated mechanism.
The anti-inflammatory role of the A2aR has been well
documented. Activation of the A2aR by high affinity orthos-
teric agonists reduces the production of pro-inflammatory
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MIP-1, MIP-2) and increases the production of the anti-
inflammatory cytokine (IL-10) in vitro (for review see [25]).
Consistent with these effects, enhancement of A2aR activa-
tion with AEA061 inhibits TNF-α production by LPS- and
PMA-stimulated monocytes/macrophages as well as MIP-
1α, MIP-1β and MCP-2 production by LPS-stimulated
splenocytes. However, we did not see a consistent in vitro
effect on the production of IL-6, IL-12 and IL-10 upon
A2aR allosteric enhancement at 12 h. This may be due to
the time-dependent nature of cytokine/chemokine expres-
sion and the need to evaluate cytokines/chemokines at
earlier time points in order to fully understand the
effects of positive allosteric enhancement of the A2aR
on immunomodulation.
Allosteric modulators have no intrinsic activity on the
receptors. In order to highlight the absolute requirement
for adenosine for AEA061-mediated A2aR potentiation,
in the cell-based cAMP assay, cells were pretreated with
adenosine deaminase and adenosine 5′ [α,β-methylene]
diphosphate to rid the cells of adenosine and to inhibit
further production of extracellular adenosine respect-
ively. In the monocyte/macrophage/splenocyte cytokine
production assays, however, exogenous addition of adeno-
sine is not needed to generate AEA061-mediated en-
hancement of A2aR activation and subsequent inhibition
of pro-inflammatory cytokine production, as adenosine is
produced both extracellularly and intracellularly by many
different cell types including monocytes/macrophages and
splenocytes during their normal cell metabolism.
In vivo activation of the A2aR also leads to a reduction
in pro-inflammatory cytokines and an increase in anti-
inflammatory cytokines levels (for review see [25]). These
effects explain the observed efficacy of A2aR orthosteric
agonists across a variety of animal models of inflammatory
disease. In a murine model of sepsis, the high affinity
orthosteric agonist, ATL313, decreases circulating plasma
levels of pro-inflammatory cytokines and chemokines such
as TNF-α, MIP-1α, MCP-1 [26] and increases the plasma
level of the anti-inflammatory cytokine IL-10 [26] within
4 h of LPS injection. Consistent with this observation, we
found that positive allosteric modulation of the A2aR upon
LPS challenge reduces significantly plasma levels of TNF-α
and MCP-1 and increases IL-10. Although we observed a
reduction in MIP-1α, the level of reduction did not reach
statistical significance.
Comparison of in vitro and in vivo anti-inflammatory
effects of AEA061 indicates a 10-fold reduction in vivo
efficacy with respect to inhibition of TNF-α production.
One can envision several possibilities for this lack of one-
to-one correlation between in vitro and in vivo efficacy of
AEA061. First, it may stem from inherent properties of
AEA061 such as plasma binding, metabolism and tissue
distribution that can reduce its in vivo availability. Second,in vitro effects of AEA061 are reflective of the impact of
A2aR potentiation on inflammatory cytokine production by
one cell type in isolation. In vivo effects of AEA061 on in-
flammatory cytokine production, however, captures a col-
lective response generated by multiple immune cells under
the influence of variety of intracellular interactions. Third,
allosteric enhancement of the A2aR by AEA061 is adeno-
sine dependent. Adenosine is rapidly degraded in vivo by
adenosine deaminase, thus has a short half-life (less than
10 seconds). Hence, in vivo, receptor enhancement may be
dictated by the endogenous adenosine and not by AEA061
levels. It is possible that in vivo, adenosine levels do not rise
to the same levels as in vitro, and that this may lead to less
inhibition of inflammatory cytokines in vivo.
In summary, we have demonstrated that the anti-
inflammatory effects of AEA061 are due solely to positive
allosteric modulation of the A2aR. First, through extensive
in vitro characterization we established that AEA061 is a
PAM of the A2aR. Second, we have shown that pharmaco-
logical blockade of the A2aR with a selective antagonist abol-
ished AEA061-mediated inhibition of TNF-α production.
Third, AEA061 did not inhibit plasma pro-inflammatory
cytokines/chemokines levels nor did it increase plasma
anti-inflammatory cytokine levels in A2aR-deficient mice.
Collectively, our data support the notion that A2aR activa-
tion can be enhanced using a PAM and is sufficient to de-
crease systemic inflammation. A PAM, such as AEA061,
can thus harness the inherent anti-inflammatory and im-
munomodulatory effects of adenosine by enhancing the
responsiveness of the A2aR to endogenously produced
adenosine.
In sepsis, reduced A2aR responsiveness to endogenous
adenosine as characterized by decreased receptor affinity
to adenosine is, at least in part, responsible for hyperactiva-
tion of polymorphonuclear leukocytes (PMNs) [27,28]. The
enhanced release of reactive oxygen species by hyperacti-
vated PMNs is a key step in the pathogenesis of sepsis.
Similarly it is likely that monocytes/macrophages also
exhibit reduced A2aR responsiveness and that allosteric
enhancement of the A2aR with AEA061 may have restored
adenosine responsiveness of the A2aR on monocytes/mac-
rophages in our endotoxemia model.
To the best of our knowledge, the present study is the
first comprehensive demonstration of positive allosteric
modulation of the A2aR. Because of its anti-inflammatory
and immunomodulatory role, the A2aR has been a thera-
peutic target for a number of disease conditions character-
ized by inflammation such as sepsis, ischemia, rheumatoid
arthritis, and wound healing [25,29]. Selective orthosteric
agonism at the A2aR as a therapeutic strategy has been
extensively studied using high affinity agonists for over
three decades [30,31]. The therapeutic utility of high affin-
ity orthosteric agonists is hindered, however, by the lack of
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Figure 9 Proposed mechanism of positive allosteric modulation of A2aR function by AEA061. The orthosteric agonist (adenosine) and the
positive allosteric modulator, AEA061, bind to topographically distinct sites at the A2AR. Unlike adenosine, AEA061 on its own has no effect on
A2AR response. However, it can enhance affinity and efficacy of adenosine and hence the receptor response. 1. Orthosteric (adenosine) agonism;
2. Allosteric (AEA061) affinity (potency) enhancement; 3. allosteric (AEA061) efficacy signaling (capacity) enhancement.
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tor activation. In contrast, allosteric enhancement of A2aRs
may provide an improved specificity and safety profile.
Specificity is enhanced since a PAM binds to a site that is
distinctly different from the orthosteric agonist (adeno-
sine)-binding site (Figure 9) and is unlikely to be conserved
among different AR subtypes; hence allosteric modulation
is less likely to produce undesired effects owing to non-
selectivity. Enhancement of safety may be anticipated since
a PAM will potentiate adenosine-mediated receptor activity
but have no intrinsic agonist activity (Figure 9). Thus, a
PAM potentiates and preserves the temporal and spatial
distribution of the adenosine-mediated physiological re-
sponse. This approach is conceivably superior to others
from a therapeutic and safety perspective as it focuses the
therapeutic benefit at the site of disease, does not employ
exogenous orthosteric agonists and preserves the natural
pattern of A2aR activation by endogenous adenosine while
enhancing receptor responsiveness.
Conclusions
Using an allosteric modulator, AEA061, we demonstrate
that the A2aR is amenable to allosteric enhancement. In-
creasing A2aR responsiveness to endogenous adenosine with
the administration of a positive allosteric modulator, that
has no intrinsic ability to activate the A2aR, can effectively
attenuate inflammation in vivo. Hence, allosteric enhance-
ment of the A2aR presents a novel, disease site-focused,
therapeutic strategy to reduce progression of disease charac-
terized by inflammation.
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